Building roadblocks between transcription and translation
Isis Pharmaceuticals (ISIS) pioneers a drug development platform that targets specific mRNA strands, after transcription, and stops them from being translated into troublesome proteins. Despite its unfortunate name, antisense technology is an extremely good method for creating the sort of highly targeted compounds the FDA likes.
Through antisense based drug development, Isis has become a highly efficient drug discovery machine. It is so efficient that Isis couldn't possibly afford to test and market even a fraction of the compounds it creates, so it doesn't
In a nutshell, Isis's business model consists of it discovering and developing drugs, then letting the grown-ups do the dirty work. Isis has licensing agreements with AstraZeneca (...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: